Investor Briefcase   
Investor Kit   
News Feeds    
Print page    Print
E-mail page    E-mail





 


PRESS RELEASES

= Add Release to Briefcase
All Releases
View Summary Savient Pharmaceuticals Reports First Quarter 2013 Financial Results
05-15-13
PDF 18.1 KB Add to Briefcase
View Summary Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
03-19-13
PDF 24.4 KB Add to Briefcase
View Summary Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
02-26-13
PDF 9.5 KB Add to Briefcase
View Summary Sobi and Savient Pharmaceuticals Announce Co-Promotion Agreement for Kineret® (anakinra) in the U.S.
02-19-13
PDF 20.1 KB Add to Briefcase
View Summary Savient's KRYSTEXXA® (pegloticase) Receives European Commission Marketing Authorization for the Treatment of Certain Patients with Chronic Tophaceous Gout
01-08-13
PDF 16.3 KB Add to Briefcase
View Summary Savient Pharmaceuticals Announces the Election of Genzyme CEO Dr. David Meeker to Its Board of Directors
01-08-13
PDF 10.2 KB Add to Briefcase
View Summary Savient Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference
01-04-13
PDF 8.8 KB Add to Briefcase
View Summary Savient Announces the Election of Robert G. Savage to its Board of Directors
12-05-12
PDF 9.7 KB Add to Briefcase
View Summary New Data Demonstrate KRYSTEXXA®-Treated Refractory Chronic Gout Patients Experienced Significantly Improved Health-Related Quality of Life
11-13-12
PDF 21.1 KB Add to Briefcase
View Summary New Data Published in Annals of the Rheumatic Diseases Confirm Long-Term Safety and Efficacy of KRYSTEXXA® for the Treatment of Refractory Chronic Gout
11-12-12
PDF 20.0 KB Add to Briefcase
View Summary Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
11-08-12
PDF 22.8 KB Add to Briefcase
View Summary Savient Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call on Thursday, November 8, 2012
10-25-12
PDF 8.8 KB Add to Briefcase
View Summary Savient Receives Positive CHMP Opinion for KRYSTEXXA® Approval in the EU
10-19-12
PDF 16.2 KB Add to Briefcase
View Summary Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
09-26-12
PDF 13.1 KB Add to Briefcase
View Summary Savient Pharmaceuticals Names John P. Hamill Chief Financial Officer
09-24-12
PDF 12.4 KB Add to Briefcase
View Summary Savient Announces Multiple Abstracts Related to KRYSTEXXA® in the Treatment of Refractory Chronic Gout to be Presented at the 2012 ACR/ARHP Annual Meeting
09-20-12
PDF 104.8 KB Add to Briefcase
View Summary Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference
09-05-12
PDF 8.8 KB Add to Briefcase
View Summary Savient Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference
08-27-12
PDF 8.9 KB Add to Briefcase
View Summary Savient Pharmaceuticals Reports Second Quarter 2012 Financial Results
08-08-12
PDF 23.9 KB Add to Briefcase
View Summary Savient Pharmaceuticals Adopts Stockholder Rights Plan
08-06-12
PDF 10.8 KB Add to Briefcase
Showing 1-20 of 76 releases Page: 1 2 3 4  See Next 20

 

Savient Pharmaceuticals, Inc. (the "Company") believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investor Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user's own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website.

The statements contained in this website contain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts included in this website are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the safety and efficacy of KRYSTEXXA®, status of our KRYSTEXXA marketing efforts and additional plans related thereto, market demand and reimbursement for KRYSTEXXA, our view of the refractory chronic gout (RCG) market size, and our market expansion plans including our MAA filing before the EMA are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, our ability to commercialize KRYSTEXXA; the risk that the market for KRYSTEXXA is smaller than we have anticipated; our ability to retain the personnel; our reliance on third parties to manufacture KRYSTEXXA; competition from existing therapies and therapies that are currently under development, including therapies that are significantly less expensive than KRYSTEXXA; our ability to gain market acceptance for KRYSTEXXA among physicians, patients, health care payers and others in the medical community; whether we are able to obtain financing, if needed; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this website to shareholders. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make.

     
CONTACT US    |    PRIVACY    |    TERMS OF USE
Copyright © 2013 Savient Pharmaceuticals, Inc. All rights reserved.